Vertex saw disappointments in 2022, that may be about to change. Profitability may improve as onerous hedging rolled off for Q4. Shares could double from here to around $18 on my estimates (range: $10 ...
Venture capital firm Vertex Ventures, backed by Singapore state investor Temasek, is set to raise nearly $500 million for a new fund that will invest in efforts to step up China's domestic tech ...
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback